CR7614A - Preparaciones de insulina acida con estabilidad mejorada - Google Patents

Preparaciones de insulina acida con estabilidad mejorada

Info

Publication number
CR7614A
CR7614A CR7614A CR7614A CR7614A CR 7614 A CR7614 A CR 7614A CR 7614 A CR7614 A CR 7614A CR 7614 A CR7614 A CR 7614A CR 7614 A CR7614 A CR 7614A
Authority
CR
Costa Rica
Prior art keywords
insulin
combinations
improved stability
acid preparations
insulin acid
Prior art date
Application number
CR7614A
Other languages
English (en)
Inventor
Brunner-Schwarz Anette
Lill Norbert
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29723248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR7614(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of CR7614A publication Critical patent/CR7614A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se refiere a una formulacion farmaceutica que comprende un polipeptido seleccionado de un grupo que comprende insulina, un metabolito de insulina, un derivado de insulina o combinaciones de los mismos ; un tensioactivo o combinaciones de dos o mas tensioactivos; opcionalmente, un conservante o combinaciones de dos o mas conservantes; y, opcionalmente un agente de isotonia, tampones u otros excipientes adicionales, o combinaciones de los mismos, teneiendo la formulacion farmaceutica un ph en el intervalo acido.
CR7614A 2002-06-18 2004-12-08 Preparaciones de insulina acida con estabilidad mejorada CR7614A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10227232A DE10227232A1 (de) 2002-06-18 2002-06-18 Saure Insulinzubereitungen mit verbesserter Stabilität

Publications (1)

Publication Number Publication Date
CR7614A true CR7614A (es) 2005-06-16

Family

ID=29723248

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7614A CR7614A (es) 2002-06-18 2004-12-08 Preparaciones de insulina acida con estabilidad mejorada

Country Status (38)

Country Link
US (4) US20040048783A1 (es)
EP (2) EP2305288B1 (es)
JP (2) JP5237522B2 (es)
KR (1) KR101040029B1 (es)
CN (2) CN1662252A (es)
AR (1) AR039688A1 (es)
AU (1) AU2003238471B2 (es)
BR (1) BRPI0311877B8 (es)
CA (1) CA2490116C (es)
CR (1) CR7614A (es)
CY (1) CY1113537T1 (es)
DE (1) DE10227232A1 (es)
DK (1) DK1517697T3 (es)
EC (1) ECSP045496A (es)
ES (2) ES2817879T3 (es)
HN (1) HN2003000184A (es)
HR (1) HRP20041200B1 (es)
IL (1) IL165788A (es)
MA (1) MA27205A1 (es)
ME (1) MEP28708A (es)
MX (1) MXPA04012233A (es)
MY (1) MY142354A (es)
NO (1) NO328567B1 (es)
NZ (1) NZ537211A (es)
OA (1) OA12870A (es)
PA (1) PA8575701A1 (es)
PE (1) PE20040560A1 (es)
PL (1) PL208773B1 (es)
PT (2) PT2305288T (es)
RS (1) RS52388B (es)
RU (1) RU2313362C2 (es)
SV (1) SV2004001556A (es)
TN (1) TNSN04249A1 (es)
TW (1) TWI315201B (es)
UA (1) UA79477C2 (es)
UY (1) UY27854A1 (es)
WO (1) WO2003105888A1 (es)
ZA (1) ZA200409273B (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
PL2319500T3 (pl) * 2004-03-12 2013-05-31 Biodel Inc Szybko działające kompozycje do dostarczania leku
WO2005115303A1 (en) * 2004-05-24 2005-12-08 Wockhardt Limited Purification of insulin-like material by reverse phase chromatography
UA75030C2 (en) * 2005-11-30 2006-03-15 Viktor Oleksandrovych Bykov Method for obtaining stable aqueous solutions of drugs
WO2007135117A2 (en) * 2006-05-24 2007-11-29 Novo Nordisk A/S Soluble, stable insulin-containing formulations
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
DE102006031955A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
EP2514412A1 (en) * 2007-04-30 2012-10-24 Novo Nordisk A/S Highly Concentrated Insulin Solutions and Compositions
JP5352596B2 (ja) * 2008-01-04 2013-11-27 バイオデル， インコーポレイテッド 組織グルコースレベルの関数としてのインスリン放出のためのインスリン製剤
AU2009203810B2 (en) 2008-01-09 2013-07-25 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
DK2229407T3 (en) 2008-01-09 2017-02-27 Sanofi Aventis Deutschland NEW INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / EFFECTS PROFILE
EP2946770A1 (en) * 2008-08-29 2015-11-25 Genzyme Corporation Controlled-released peptide formulations
US20100069292A1 (en) * 2008-09-02 2010-03-18 Biodel, Inc. Insulin with a basal release profile
MX344293B (es) 2008-10-17 2016-12-13 Sanofi Aventis Deutschland Combinacion de una insulina y un agonista de glp-1.
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
MY159865A (en) * 2009-07-06 2017-02-15 Sanofi Aventis Deutschland Aqueous insulin preparations containing methionine
BR112012011403B8 (pt) 2009-11-13 2021-05-25 Sanofi Aventis Deutschland composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
PT2498802E (pt) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
US8637458B2 (en) 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
WO2011156476A2 (en) * 2010-06-08 2011-12-15 Biodel Inc. Insulin with a basal release profile
RU2546520C2 (ru) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
CN102188367B (zh) * 2011-01-05 2012-11-07 山东新时代药业有限公司 一种甘精胰岛素注射液及其制备方法
BR112013018269A2 (pt) 2011-01-20 2017-06-06 Zealand Pharma As combinação de análogos acilados do glucagon com análogos da insulina
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
MX2014001190A (es) * 2011-08-10 2014-05-12 Adocia Solucion inyectable de al menos insulina basal.
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013063283A1 (en) 2011-10-25 2013-05-02 Corning Incorporated Delamination resistant pharmaceuticals glass containers containing active pharmaceutical ingredients
US10350139B2 (en) 2011-10-25 2019-07-16 Corning Incorporated Pharmaceutical glass packaging assuring pharmaceutical sterility
CN107583039A (zh) 2012-01-09 2018-01-16 阿道恰公司 Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
PL2919804T3 (pl) 2012-11-13 2018-07-31 Adocia Szybko działająca formulacja insuliny zawierająca podstawiony związek anionowy
CA2889165A1 (en) * 2012-12-19 2014-06-26 Wockhardt Limited A stable aqueous composition comprising human insulin or an analogue or derivative thereof
JP2016503771A (ja) 2012-12-21 2016-02-08 サノフイ エキセンジン−４誘導体
AU2013368990B2 (en) 2012-12-26 2017-05-18 Wockhardt Limited Pharmaceutical composition
TWI641381B (zh) * 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
CA2907848A1 (en) 2013-04-03 2014-10-09 Sanofi Treatment of diabetes mellitus by long-acting formulations of insulins
US9713572B2 (en) 2013-04-24 2017-07-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717649B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707155B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707153B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717648B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
SG11201604708VA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2015104314A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
CN105899190B (zh) 2014-01-09 2022-06-14 赛诺菲 门冬胰岛素的稳定化药物制剂
JP7173953B2 (ja) * 2014-01-09 2022-11-16 サノフイ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
MA39301A1 (fr) 2014-01-20 2018-01-31 Hanmi Pharmaceutical Co Ltd Insuline à action prolongée et utilisation associée
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN107108711B (zh) * 2014-10-23 2021-11-23 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
LT3229828T (lt) 2014-12-12 2023-06-12 Sanofi-Aventis Deutschland Gmbh Insulino glargino/liksisenatido fiksuoto santykio kompozicija
TW201630622A (zh) 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
WO2017179615A1 (ja) * 2016-04-15 2017-10-19 富士フイルム株式会社 マイクロニードルアレイ及びマイクロニードルアレイの製造方法
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
JP7158378B2 (ja) 2016-09-23 2022-10-21 ハンミ ファーマシューティカル カンパニー リミテッド インスリン受容体との結合力が減少された、インスリンアナログ及びその用途
US11752216B2 (en) 2017-03-23 2023-09-12 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof
CN110662551B (zh) 2017-06-01 2023-07-18 伊莱利利公司 速效胰岛素组合物
JP2022534926A (ja) * 2019-05-29 2022-08-04 サノフイ 薬物送達デバイス

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
US3758683A (en) * 1971-04-30 1973-09-11 R Jackson Insulin product
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
GB1554157A (en) 1975-06-13 1979-10-17 Takeda Chemical Industries Ltd Stable insulin preparation for intra nasal administration
GB1527605A (en) * 1975-08-20 1978-10-04 Takeda Chemical Industries Ltd Insulin preparation for intranasal administration
JPS52156913A (en) * 1976-06-21 1977-12-27 Toko Yakuhin Kogyo Kk Production of injectionable medicine
DE3064888D1 (en) 1979-04-30 1983-10-27 Hoechst Ag Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
JPS55153712A (en) * 1979-05-18 1980-11-29 Kao Corp Insulin pharmaceutical preparation and its production
DE3033127A1 (de) 1980-09-03 1982-04-08 Hoechst Ag, 6000 Frankfurt Neue analoga des insulins
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
AU558474B2 (en) 1981-07-17 1987-01-29 Nordisk Insulinlaboratorium A stable aqueous, therapeutic insulin preparation and a process for preparing it
NL193099C (nl) 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
DE3316363A1 (de) 1983-05-05 1984-11-08 Deutsche Babcock Anlagen Ag, 4200 Oberhausen Walzenrost fuer muellverbrennungsanlagen
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
US5177068A (en) * 1984-04-19 1993-01-05 National Research Development Corporation Pharmaceutical compositions
CA1244347A (en) 1984-05-29 1988-11-08 Eddie H. Massey Stabilized insulin formulations
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
ATE50502T1 (de) * 1984-06-09 1990-03-15 Hoechst Ag Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung.
DE3440988A1 (de) 1984-11-09 1986-07-10 Hoechst Ag, 6230 Frankfurt Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung
DK113585D0 (da) 1985-03-12 1985-03-12 Novo Industri As Nye peptider
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
DK347086D0 (da) 1986-07-21 1986-07-21 Novo Industri As Novel peptides
IL78425A (en) 1985-04-15 1991-05-12 Lilly Co Eli Intranasal formulation containing insulin
DE3526995A1 (de) 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3541856A1 (de) 1985-11-27 1987-06-04 Hoechst Ag Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
US5496924A (en) * 1985-11-27 1996-03-05 Hoechst Aktiengesellschaft Fusion protein comprising an interleukin-2 fragment ballast portion
CA1275922C (en) 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
DE3544295A1 (de) 1985-12-14 1987-06-19 Bayer Ag Thermoplastische formmassen mit hoher kriechstromfestigkeit
JP2606915B2 (ja) 1987-02-25 1997-05-07 ノボ ノルディスク アクティーゼルスカブ 新規インシュリン誘導体
US5034415A (en) * 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
DE3726655A1 (de) * 1987-08-11 1989-02-23 Hoechst Ag Verfahren zur isolierung basischer proteine aus proteingemischen, welche solche basischen proteine enthalten
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
DE3827533A1 (de) 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5210038A (en) * 1988-12-22 1993-05-11 Becton, Dickinson And Company Multiplate subculture solid media devices
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
US4886164A (en) * 1989-06-16 1989-12-12 Enviro Med, Inc. Containers for medical waste
US5358857A (en) * 1989-08-29 1994-10-25 The General Hospital Corp. Method of preparing fusion proteins
WO1991016929A1 (en) * 1990-05-10 1991-11-14 Novo Nordisk A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
DK155690D0 (da) * 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK10191D0 (da) * 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US5614219A (en) * 1991-12-05 1997-03-25 Alfatec-Pharma Gmbh Oral administration form for peptide pharmaceutical substances, in particular insulin
DE4140186C2 (de) * 1991-12-05 1996-07-04 Alfatec Pharma Gmbh Perorale Applikationsform für Peptidarzneistoffe, insbesondere Insulin
US6468959B1 (en) * 1991-12-05 2002-10-22 Alfatec-Pharm Gmbh Peroral dosage form for peptide containing medicaments, in particular insulin
ES2097426T3 (es) 1992-12-02 1997-04-01 Hoechst Ag Procedimiento para la obtencion de proinsulina con puentes de cistina correctamente unidos.
PL310007A1 (en) 1992-12-18 1995-11-13 Lilly Co Eli Insulin analogues
JP2743761B2 (ja) * 1993-03-19 1998-04-22 松下電器産業株式会社 走査型プローブ顕微鏡および原子種同定方法
US5514656A (en) * 1993-05-28 1996-05-07 Abbott Laboratories Method of providing enteral nutritional support for patients undergoing radiation therapy and/or chemotherapy
US5882944A (en) 1993-06-23 1999-03-16 The Regents Of The University Of California Methods for G protein coupled receptor activity screening
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
EP0637073A1 (en) * 1993-07-29 1995-02-01 STMicroelectronics S.r.l. Process for realizing low threshold P-channel MOS transistors for complementary devices (CMOS)
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
DE4405179A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
DE4406467A1 (de) * 1994-02-23 1995-08-24 Dragoco Gerberding Co Ag Isolongifolanol-Derivate, ihre Herstellung und ihre Verwendung
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5559094A (en) * 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
ATE197398T1 (de) 1994-09-09 2000-11-11 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freigabe eines metallsalz eines peptids
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5707641A (en) * 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
US5496164A (en) * 1994-10-20 1996-03-05 The Conair Group, Inc. In-line tubing die
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
WO1996041606A2 (en) 1995-06-08 1996-12-27 Therexsys Limited Improved pharmaceutical compositions for gene therapy
AU6242096A (en) * 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
DE19545257A1 (de) * 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5948751A (en) * 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
US5656772A (en) * 1996-07-19 1997-08-12 Markel; Philip A. Gas pressure gauge clamp
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
DE69834028T2 (de) 1997-03-20 2006-12-07 Novo Nordisk A/S Zinkfreie insulinkristalle für die verwendung in medikamenten, die über die lunge verabreicht werden.
US6310038B1 (en) * 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
CO4750643A1 (es) * 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
EP1044016B1 (en) * 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
UA65636C2 (uk) 1998-10-16 2004-04-15 Ново Нордіск А/С Стабільні концентровані препарати інсуліну для доставки через легені
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US6489292B1 (en) * 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
DE19908041A1 (de) * 1999-02-24 2000-08-31 Hoecker Hartwig Kovalent verbrückte Insulindimere
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
ATE288765T1 (de) 1999-12-16 2005-02-15 Lilly Co Eli Polypeptidzusammensetzungen mit verbesserter stabilität
WO2001052937A1 (en) * 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
JP4711520B2 (ja) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
US6267481B1 (en) * 2000-04-05 2001-07-31 Jeng Tai Umbrella Mfg., Corp. Illumination assembly for an umbrella
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
CN1160122C (zh) 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US6960551B2 (en) * 2002-08-23 2005-11-01 Exxonmobil Research And Engineering Company Functionalized periodic mesoporous materials, their synthesis and use
US6906897B1 (en) * 2003-02-28 2005-06-14 Western Digital Technologies, Inc. Disk drive including an actuator main coil and an actuator secondary coil with a lateral segment and method of operating same

Also Published As

Publication number Publication date
TWI315201B (en) 2009-10-01
CN102133393B (zh) 2014-05-28
ES2397158T3 (es) 2013-03-05
ES2817879T3 (es) 2021-04-08
US20040048783A1 (en) 2004-03-11
KR20050010939A (ko) 2005-01-28
ME00180B (me) 2010-10-10
US7713930B2 (en) 2010-05-11
UA79477C2 (en) 2007-06-25
ECSP045496A (es) 2005-03-10
RS105704A (sr) 2007-02-05
CN102133393A (zh) 2011-07-27
PT1517697E (pt) 2012-12-17
US20050171009A1 (en) 2005-08-04
IL165788A0 (en) 2006-01-15
EP1517697B1 (de) 2012-10-10
RS52388B (sr) 2013-02-28
EP2305288A2 (de) 2011-04-06
OA12870A (en) 2006-09-15
PA8575701A1 (es) 2004-02-07
UY27854A1 (es) 2003-12-31
MA27205A1 (fr) 2005-01-03
EP2305288A3 (de) 2013-12-11
PT2305288T (pt) 2020-09-16
EP1517697A1 (de) 2005-03-30
US7476652B2 (en) 2009-01-13
HN2003000184A (es) 2008-01-15
DE10227232A1 (de) 2004-01-15
US20090082255A1 (en) 2009-03-26
TNSN04249A1 (en) 2007-03-12
JP2005532365A (ja) 2005-10-27
ZA200409273B (en) 2005-08-31
KR101040029B1 (ko) 2011-06-10
SV2004001556A (es) 2004-03-08
RU2005100959A (ru) 2005-06-27
MEP28708A (en) 2010-10-10
EP2305288B1 (de) 2020-07-15
AR039688A1 (es) 2005-03-09
HRP20041200A2 (en) 2005-06-30
US20100216692A1 (en) 2010-08-26
MY142354A (en) 2010-11-15
WO2003105888A1 (de) 2003-12-24
JP5237522B2 (ja) 2013-07-17
RU2313362C2 (ru) 2007-12-27
TW200409642A (en) 2004-06-16
BR0311877A (pt) 2005-04-05
CY1113537T1 (el) 2016-06-22
NO20050036L (no) 2005-01-04
JP2011006492A (ja) 2011-01-13
NZ537211A (en) 2006-08-31
DK1517697T3 (da) 2013-01-28
NO328567B1 (no) 2010-03-22
CA2490116A1 (en) 2003-12-24
MXPA04012233A (es) 2005-02-25
CA2490116C (en) 2012-07-24
PL208773B1 (pl) 2011-06-30
CN1662252A (zh) 2005-08-31
PL372072A1 (en) 2005-07-11
BRPI0311877B1 (pt) 2017-04-11
IL165788A (en) 2011-05-31
AU2003238471A1 (en) 2003-12-31
BRPI0311877B8 (pt) 2021-05-25
HRP20041200B1 (hr) 2013-05-31
AU2003238471B2 (en) 2009-02-19
PE20040560A1 (es) 2004-09-24

Similar Documents

Publication Publication Date Title
CR7614A (es) Preparaciones de insulina acida con estabilidad mejorada
BRPI0208210B8 (pt) preparação de insulina pobre em zinco e isenta de zinco com estabilidade aperfeiçoada
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
CY1114631T1 (el) Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο
ATE382057T1 (de) Stabile formulierung von modifiziertem glp-1
BR0112461A (pt) Composições que contém componentes terapeuticamente ativos tendo uma solubilidade aumentada
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
NO20054440L (no) Flytende formuleringer av tumornekrosefaktorbindende proteiner
DK1259226T3 (da) Anæstetiske formuleringer
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
DE60143363D1 (de) Pharmazeutische zusammensetzungen, die die immunogenität von schwach immunogenen antigenen fördern
DK1171124T4 (da) Anthelmintpræparater
ECSP930933A (es) Composicion farmaceutica y procedimiento para prepararla
CU22836A3 (es) Sistema de gel de nimesulida para uso tópico
DE60232271D1 (de) Wässrige pharmazeutische formulierungen von wasserlöslichen prodrugs von propofol-verbindungen
EA200200415A1 (ru) Композиция фармацевтического носителя
RS50074B (sr) Farmaceutski preparat koji sadrži paracetamol i drotaverin
AR013202A1 (es) Vacunas no acuosas
AR012019A1 (es) Compuesto de criptoficina y su uso para preparar un medicamento
CL2015003221A1 (es) Formulacion farmaceutica estable para administracion intratecal que comprende una proteina arilsufatasa a (asa), sal y un tensoactivo de polisorbato y/o un agente amortiguador, y que ademas puede contener un agente estabilizante; contenedor que comprende dicha formulacion; uso para tratar la enfermedad leucodistrofia metacromatica (mld)
CR10221A (es) Una composición sólida de taxano liofilizada, un procedimiento para preparar dicha composición sólida, una formulación farmacéutica y un conjunto (kit) de dicha formulación